Eleven Biotherapeutics (EBIO) Given a $2.00 Price Target by HC Wainwright Analysts

Big Money Sentiment increased to 2.25 in Q4 2017. It has change of 1.70, from 2017Q3's 0.55. It is positive, as 2 investors sold Eleven Biotherapeutics, Inc. shares while 2 reduced holdings.

An institutional investor recently raised its position in Eleven Biotherapeutics stock. Funds hold 1.80 million shares thus 48.09% more from 2017Q3's 1.21 million shares. Morgan Stanley, a New York-based fund reported 12,062 shares. (NASDAQ:EBIO). Fiduciary Tru Comm owns 20,000 shs or 0% of their U.S. capital. Northern Tru Corporation holds 0% in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO). Blackrock reported 445,463 shares or 0% of all its holdings. 600 were accumulated by Citigroup. Panagora Asset Mngmt invested in 0% or 3,475 shs. Citadel Advsr Limited Liability Co, a Illinois-based fund reported 15,372 shs. Two Sigma Ltd invested 0% of its portfolio in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO). Geode Cap Management Ltd Liability Corp holds 56,222 shs. Royal Bancorp Of Canada invested in 0% or 505 shs. Parallax Volatility Advisers Limited Partnership has 36,761 shs.

HC Wainwright set a $2.00 price target on Eleven Biotherapeutics (NASDAQ:EBIO) in a report published on Wednesday, April 18th. On Apr, 28 it was announced by Barchart.com. The company has market cap of $108.20 million. The brokerage now has a "buy" rating on the biopharmaceutical company's stock.

Eleven Biotherapeutics stock opened at $2.51 on Thursday. (NASDAQ:EBIO)'s earnings report, according to Zacks. The company traded as low as $2.60 and last traded at $2.41, with a volume of 5325143 shares changing hands. They expect $-0.13 EPS, up 48.00 % or $0.12 from last year's $-0.25 per share.

Eleven Biotherapeutics, Inc, a biologic oncology company, focuses on the design and development of targeted protein therapeutics (TPTs). It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. The company's lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Notícias recomendadas

  • How Analysts Rated The Blackstone Group LP (NYSE:BX) Last Week?

    In related news, insider Kathleen Skero sold 11,000 shares of the company's stock in a transaction dated Monday, August 15th. The stock of GTT Communications, Inc. 22,000 shares were sold by Finley John G, worth $751,300 on Friday, February 23.

    BlackRock (NYSE:BLK) PT Raised to $682.00 at Credit Suisse Group

    Advantage Investment Management LLC boosted its stake in BlackRock by 54.9% during the 4th quarter. (NYSE:BLK) for 27,740 shares. Wellington Shields And Com Ltd Liability Corporation stated it has 0.28% of its portfolio in CVS Health Corporation (NYSE:CVS).

    EPS for RadNet, Inc. (RDNT) Expected At $0.04 as of May, 9

    The business had revenue of $235.50 million during the quarter, compared to analyst estimates of $228.46 million. BidaskClub raised RadNet from a "buy" rating to a "strong-buy" rating in a research note on Friday, March 23rd.
  • Patterson-UTI (PTEN) Lifted to Hold at BidaskClub

    Shareholders of record on Thursday, June 7th will be issued a dividend of $0.04 per share. (NYSE:IT) or 12,115 shares. The investment managers in our database now possess: 212.21 million shares, up from 207.11 million shares in 2017Q3.

    Incyte (INCY) Scheduled to Post Quarterly Earnings on Tuesday

    The biopharmaceutical company reported $0.02 EPS for the quarter, beating the Zacks' consensus estimate of ($0.52) by $0.54. Following the sale, the insider now directly owns 12,922 shares in the company, valued at approximately $1,105,606.32.

    Advanced Micro Devices, Inc. (AMD) EPS Estimated At $0.06

    The stock has actually weakened in the past week, as the company has gathered a -0.73% return in the past 5 trading days. The total market cap for the stock is $11.10B its price-to-earnings-growth ratio reads 2.08 while it has a beta of 2.82.
  • POLICE RAID: Two dead, 112 rescued and 36 arrested at Usafi

    POLICE RAID: Two dead, 112 rescued and 36 arrested at Usafi

    The crime shocked Ugandans, and President Yoweri Museveni ordered intelligence agencies to lead an investigation into her murder. Police said that "in the operation, two of the armed suspects were shot dead as they attacked the officers in the operation".

    Laboratory Corp. of America (LH) Upgraded by ValuEngine to Buy

    Qs Investors Limited Liability Corp has invested 0.01% of its portfolio in Laboratory Corporation of America Holdings (NYSE:LH). Ameriprise stated it has 0% of its portfolio in OncoMed Pharmaceuticals, Inc. 60,475 are held by Connor Clark Lunn Mgmt Ltd.
    Iowa Supreme Court rules against DOT in speed camera case

    Iowa Supreme Court rules against DOT in speed camera case

    In addition, the DOT will no longer enforce its rules that require cities to justify camera placement based on traffic safety. The City of Muscatine certainly appreciates the decision made today by the Iowa Supreme Court.
  • Tulane CB Perry Nickerson drafted by the New York Jets

    Tulane CB Perry Nickerson drafted by the New York Jets

    After a redshirt season, Fatukasi started three of 12 games played in 2014, making 31 tackles, three for loss. Nickerson's selection marks the second straight year the the a Green Wave player has been taken in the draft.

    Anticipated $0.84 EPS for Tiffany & Co. (TIF) on May, 23

    Nine research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. Piedmont Advsrs Limited Company invested in 0.56% or 207,665 shares. 9,572 were accumulated by Benjamin F Edwards And Com.

    BidaskClub Upgrades Flexion Therapeutics (FLXN) to "Hold"

    State Board Of Administration Of Florida Retirement stated it has 0% in Flexion Therapeutics, Inc. (NASDAQ:FLXN) or 3,690 shares. The specialty pharmaceutical company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.27).

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.